235 related articles for article (PubMed ID: 36834477)
1. Measurable Residual Disease (MRD) as a Surrogate Efficacy-Response Biomarker in AML.
Meddi E; Savi A; Moretti F; Mallegni F; Palmieri R; Paterno G; Buzzatti E; Del Principe MI; Buccisano F; Venditti A; Maurillo L
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834477
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia.
Aitken MJL; Ravandi F; Patel KP; Short NJ
J Hematol Oncol; 2021 Sep; 14(1):137. PubMed ID: 34479626
[TBL] [Abstract][Full Text] [Related]
3. Measurable Residual Disease Assessment as a Surrogate Marker in New Drug Development in Acute Myeloid Leukemia.
Gui G; Hourigan CS
Cancer J; 2022 Jan-Feb 01; 28(1):73-77. PubMed ID: 35072377
[TBL] [Abstract][Full Text] [Related]
4. Achieving MRD negativity in AML: how important is this and how do we get there?
Hourigan CS
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):9-14. PubMed ID: 36485093
[TBL] [Abstract][Full Text] [Related]
5. Measurable residual disease testing in acute myeloid leukaemia.
Hourigan CS; Gale RP; Gormley NJ; Ossenkoppele GJ; Walter RB
Leukemia; 2017 Jul; 31(7):1482-1490. PubMed ID: 28386105
[TBL] [Abstract][Full Text] [Related]
6. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
7. Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication.
Tiong IS; Loo S
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902217
[TBL] [Abstract][Full Text] [Related]
8. Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations.
Walter RB; Ofran Y; Wierzbowska A; Ravandi F; Hourigan CS; Ngai LL; Venditti A; Buccisano F; Ossenkoppele GJ; Roboz GJ
Leukemia; 2021 Jun; 35(6):1529-1538. PubMed ID: 33758317
[TBL] [Abstract][Full Text] [Related]
9. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.
Platzbecker U; Middeke JM; Sockel K; Herbst R; Wolf D; Baldus CD; Oelschlägel U; Mütherig A; Fransecky L; Noppeney R; Bug G; Götze KS; Krämer A; Bochtler T; Stelljes M; Groth C; Schubert A; Mende M; Stölzel F; Borkmann C; Kubasch AS; von Bonin M; Serve H; Hänel M; Dührsen U; Schetelig J; Röllig C; Kramer M; Ehninger G; Bornhäuser M; Thiede C
Lancet Oncol; 2018 Dec; 19(12):1668-1679. PubMed ID: 30442503
[TBL] [Abstract][Full Text] [Related]
10. Highlighting the Prognostic Importance of Measurable Residual Disease Among Acute Myeloid Leukemia Risk Factors.
Narlı Özdemir Z; Şahin U; Dalva K; Baltacı MA; Uslu A; Öztürk C; Cengiz Seval G; Toprak SK; Kurt Yüksel M; Topçuoğlu P; Arslan Ö; Özcan M; Beksaç M; İlhan O; Gürman G; Civriz Bozdağ S
Turk J Haematol; 2021 Jun; 38(2):111-118. PubMed ID: 33112099
[TBL] [Abstract][Full Text] [Related]
11. The minimal that kills: Why defining and targeting measurable residual disease is the "Sine Qua Non" for further progress in management of acute myeloid leukemia.
Bewersdorf JP; Shallis RM; Boddu PC; Wood B; Radich J; Halene S; Zeidan AM
Blood Rev; 2020 Sep; 43():100650. PubMed ID: 31883804
[TBL] [Abstract][Full Text] [Related]
12. NGS-defined measurable residual disease (MRD) after initial chemotherapy as a prognostic biomarker for acute myeloid leukemia.
Li Y; Solis-Ruiz J; Yang F; Long N; Tong CH; Lacbawan FL; Racke FK; Press RD
Blood Cancer J; 2023 Apr; 13(1):59. PubMed ID: 37088803
[TBL] [Abstract][Full Text] [Related]
13. Minimal/Measurable Residual Disease Monitoring in
Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
[TBL] [Abstract][Full Text] [Related]
14. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.
Terwijn M; van Putten WL; Kelder A; van der Velden VH; Brooimans RA; Pabst T; Maertens J; Boeckx N; de Greef GE; Valk PJ; Preijers FW; Huijgens PC; Dräger AM; Schanz U; Jongen-Lavrecic M; Biemond BJ; Passweg JR; van Gelder M; Wijermans P; Graux C; Bargetzi M; Legdeur MC; Kuball J; de Weerdt O; Chalandon Y; Hess U; Verdonck LF; Gratama JW; Oussoren YJ; Scholten WJ; Slomp J; Snel AN; Vekemans MC; Löwenberg B; Ossenkoppele GJ; Schuurhuis GJ
J Clin Oncol; 2013 Nov; 31(31):3889-97. PubMed ID: 24062400
[TBL] [Abstract][Full Text] [Related]
15. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
[TBL] [Abstract][Full Text] [Related]
16. NPM1-mutation-based measurable residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical predictor of the prognosis of acute myeloid leukemia.
Marumo A; Wakita S; Morita K; Oh I; Kako S; Toya T; Najima Y; Doki N; Kanda J; Kuroda J; Mori S; Satake A; Usuki K; Uoshima N; Kobayashi Y; Kawata E; Nagao Y; Shono K; Shibusawa M; Tadokoro J; Hagihara M; Uchiyama H; Kubota Y; Kimura S; Motomura S; Hashimoto A; Muto H; Sato E; Ogata M; Mitsuhashi K; Ando J; Date K; Fujiwara Y; Terada K; Yui S; Arai K; Kitano T; Miyata M; Ohashi K; Kanda Y; Yamaguchi H
Int J Hematol; 2022 Aug; 116(2):199-214. PubMed ID: 35377134
[TBL] [Abstract][Full Text] [Related]
17. Minimal residual disease in acute myeloid leukemia: coming of age.
Paietta E
Hematology Am Soc Hematol Educ Program; 2012; 2012():35-42. PubMed ID: 23233558
[TBL] [Abstract][Full Text] [Related]
18. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia.
Chen X; Xie H; Wood BL; Walter RB; Pagel JM; Becker PS; Sandhu VK; Abkowitz JL; Appelbaum FR; Estey EH
J Clin Oncol; 2015 Apr; 33(11):1258-64. PubMed ID: 25732155
[TBL] [Abstract][Full Text] [Related]
19. Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity.
Bazinet A; Kadia T; Short NJ; Borthakur G; Wang SA; Wang W; Loghavi S; Jorgensen J; Patel K; DiNardo C; Daver N; Alvarado Y; Haddad FG; Pierce S; Nogueras Gonzalez G; Maiti A; Sasaki K; Yilmaz M; Thompson P; Wierda W; Garcia-Manero G; Andreeff M; Jabbour E; Konopleva M; Huang X; Kantarjian H; Ravandi F
Blood Adv; 2023 Jul; 7(13):3284-3296. PubMed ID: 36884300
[TBL] [Abstract][Full Text] [Related]
20. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia.
Freeman SD; Virgo P; Couzens S; Grimwade D; Russell N; Hills RK; Burnett AK
J Clin Oncol; 2013 Nov; 31(32):4123-31. PubMed ID: 24062403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
